Date: 2015-10-05
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Society of Nephrology Kidney Week 2015
Company: Atara Biotherapeutics (USA - CA)
Product: PINTA 745
Action
mechanism: peptibody. PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth. Through its biologic activity in blocking myostatin activity and in mitigating inflammatory mediators, PINTA 745 may have the potential to decrease the manifestations of protein-energy wasting, reduce the rates of serious complications, and improve functional status.
Disease: chronic kidney disease
Therapeutic area: Kidney diseases - Renal diseases
Country:
Trial details:
Latest
news: * On October 5, 2015, Atara Biotherapeutics, a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, announced that its collaborating investigators at Baylor College of Medicine will present at the American Society of Nephrology (ASN) Kidney Week 2015. In a pre-clinical study of mice with Chronic Kidney Disease (CKD), muscle fibrosis was prevented by administration of the anti-myostatin peptibody, PINTA 745. The meeting will take place from November 3-8, 2015 in San Diego, California. (Myostatin Stimulates Progenitor Cells to Differentiate into Fibrocytes leading to Muscle Fibrosis in Chronic Kidney Disease - Publication Number: 3307
